Anavex Life Sciences Corp (AVXL)

[Amatuer17]

The report shows there are 50 million ALZ diagnoses patients . You used the ration of 1:4 as the diagnosed to come to 200 million and went back to 100 million.

First - this number is not relevant and not correct for many reasons
- no one can treat 100 million people in 1st or 2nd or 3rd year of approval
- majority of people may not be afford the cost of the drug.
- the key target audience that can pay the cost of this drug are in US-Japan where you have 5 million patients

So the target patient population really drops severely to 2 to 5 million for 1st 2 years.